<DOC>
	<DOCNO>NCT00100958</DOCNO>
	<brief_summary>RATIONALE : Chemoprevention use certain drug keep cancer forming , grow , come back . The use indole-3-carbinol may prevent cancer . PURPOSE : This randomized phase I trial study side effect best dose indole-3-carbinol see well work compare placebo prevent cancer healthy participant .</brief_summary>
	<brief_title>Indole-3-Carbinol Preventing Cancer Healthy Participants</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose indole-3-carbinol healthy participant . - Determine safety tolerability drug participant . - Determine pharmacokinetics drug participant . Secondary - Determine effect drug select marker sexual function participant . - Determine effect drug marker susceptibility cancer participant . OUTLINE : This randomize , double-blind , placebo-controlled , dose-escalation study . Participants dose level randomize 1 2 treatment arm . - Arm I : Participants receive single dose oral indole-3-carbinol day 1 . - Arm II : Participants receive single dose oral placebo day 1 . Cohorts 3 participant receive escalate dos indole-3-carbinol maximum tolerate dose ( MTD ) determine . The MTD define dose precede 1 3 participant experience dose-limiting toxicity . An additional cohort 3 participant treat MTD . Participants follow day 2 , 3 , 6 . PROJECTED ACCRUAL : A total 24 participant ( 18 arm I 6 arm II ) accrue study .</detailed_description>
	<mesh_term>Indole-3-carbinol</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Healthy participant Nonsmoker No drug abuse , determine urine cotinine baseline drug screen PATIENT CHARACTERISTICS : Age 18 70 Performance status Not specify Life expectancy At least 12 month Hematopoietic Absolute granulocyte count &gt; 1,500/mm^3 Hemoglobin &gt; 10 g/dL Hepatic Bilirubin &lt; 1.8 mg/dL AST ALT &lt; 110 U/L Alkaline phosphatase &lt; 300 U/L Renal Creatinine &lt; 2.0 mg/dL Albumin &gt; 3.0 g/dL Pulmonary No asthma Other Not pregnant nursing Negative pregnancy test Weight within 20 % ideal body weight Metropolitan Life table No serious drug allergies No arthritis No acute , unstable , chronic , recur medical condition No strict vegetarians No diabetes No evidence active malignancy No serious intolerance allergy Mild seasonal allergy allow No serious acute chronic illness None follow chronic condition : Headaches Dysphoria Fatigue Dizziness Blurred vision Insomnia Rhinorrhea Nausea Vomiting Abdominal pain Diarrhea Constipation Premenstrual syndrome Cessation menses within past 10 day ( menstruate woman ) PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior chemotherapy Endocrine therapy Concurrent oral contraceptive allow Radiotherapy Not specify Surgery Not specify Other More 21 day since prior medication , herbal product , dietary supplement , highdose vitamin More 3 month since prior investigational drug At least 14 day since prior concurrent ingestion cruciferous vegetable , include follow : Broccoli Cabbage , include coleslaw Cauliflower Bokchoy Brussels sprout Collards Kale Kohlrabi Mustard green Rutabaga Turnip Watercress At least 7 day since prior concurrent alcohol consumption At least 48 hour since prior ingestion grapefruitcontaining food beverages No concurrent chronic drug therapy No concurrent supplement , include dietary supplement , vitamin , herbal product , overthecounter medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2006</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>